argenx opens Phase 1 bioequivalence trial comparing efgartigimod autoinjector to prefilled syringe
A new argenx-sponsored study in healthy adults is testing whether efgartigimod PH20 SC delivered by autoinjector matches blood levels seen with the prefilled syringe.
This week's update covers one new argenx registry entry.
- argenx is recruiting for a Phase 1, open-label, randomized, single-dose, two-period crossover study comparing efgartigimod PH20 SC delivered by autoinjector versus prefilled syringe in healthy adult participants1 (NCT07782775). The study has an enrollment target of 32 participants1, started on 2026-06-19, and lists an estimated primary completion date of 2026-09-181. Each participant will receive both the autoinjector and prefilled syringe formulations of efgartigimod PH20 SC, in a different order for each1, with Cmax and AUC0-inf as the primary pharmacokinetic outcomes1.
Fact check notes
- Imprecise
argenx opens Phase 1 bioequivalence trial comparing efgartigimod autoinjector to prefilled syringe
Study status is 'recruiting' with an actual start date of 2026-06-19, about two months before the record was first posted (2026-08-24). 'Opens' implies a new launch, but the trial had already started recruiting before this registry entry appeared; not a major discrepancy but slightly overstates recency. - Checker's noteHeadline uses 'opens' though the study's actual start date (2026-06-19) precedes the first-posted date (2026-08-24) by about two months, meaning the trial was already underway rather than newly opening.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.